Caris Life Sciences,�Inc. (CAI) vs Vaxcyte, Inc. (PCVX)
Caris Life Sciences,�Inc. and Vaxcyte, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and Vaxcyte, Inc. are of similar size ($9.1B and $8.5B). Vaxcyte, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 85.1×. Caris Life Sciences,�Inc. has the higher net margin (8.15% vs 0.00%) and the higher return on invested capital (50.0% vs −57.3%). Across the 14 metrics below, Caris Life Sciences,�Inc. leads on 11 and Vaxcyte, Inc. on 3.
Valuation
Profitability
| Metric | CAI | PCVX | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.66% | 0.00% | 65.16% |
| Operating margin | 15.49% | 0.00% | 0.00% |
| Net margin | 8.15% | 0.00% | 0.00% |
| Free cash flow margin | 12.53% | 0.00% | 0.00% |
| Return on equity | 15.45% | (36.51%) | (57.72%) |
| Return on assets | 7.39% | (33.03%) | (49.22%) |
| Return on invested capital | 49.95% | (57.30%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack